D Biotherapeutics LLC Profile last edited on: 10/25/23
CAGE: 8X8A2
UEI: LHG2E1VG7PY6
Business Identifier: Delivering safe, functional, and personalized living tissues and organs, engineered on-demand for patients 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Salt Lake
Congr. District: 01
County: Salt Lake
Public Profile
A clinical-stage biotechnology company in regenerative medicine the D Biotherapeutics LLC assembled team are using novel 3D-bioprinting and materials technologies to deliver safe, functional and personalized living tissues and organs, engineered on-demand for patients. Developing living tissue implants with structural and functional integrity with a four-part technology platform, including: novel and proprietary 3D-bioprinter (GMPrint), bio-ink (ColVivo), specialized cell culture system, and implantable protective shell (Overshell Technology), management are committed to providing healthcare professionals with safe and functional implant solutions delivering optimal patient outcomes, management are breaking new ground with a clinical trial underway to treat Microtia, three additional programs nearing the clinic, and multiple life-changing treatment approaches in developme
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 1 | NIH | $295,894 | |
| Project Title: A Potent D-peptide Inhibitor of TNF? for Treatment of Rheumatoid Arthritis | ||||
| 2022 | 1 | NIH | $299,981 | |
| Project Title: An oral TNFα inhibitor for inflammatory bowel disease | ||||
| 2022 | 1 | NIH | $301,488 | |
| Project Title: A Next-Generation Therapeutic for Treatment of TNFα-mediated Inflammatory Diseases | ||||
Key People / Management
Larry Bonassar -- Co-Founder
Daniel Cohen -- Chief Executive Officer & Co-Founder
Hod Lipson -- Co-Founder
Colin Mcdonough -- Chief Financial Officer
Alan Wahl
Harlan Weisman -- Executive Chairman
Brett Welch
Daniel Cohen -- Chief Executive Officer & Co-Founder
Hod Lipson -- Co-Founder
Colin Mcdonough -- Chief Financial Officer
Alan Wahl
Harlan Weisman -- Executive Chairman
Brett Welch
Company News
There are no news available.
